March 8, 2024Open Access
Use of Sodium‐Glucose Cotransporter‐2 Inhibitors and Angiotensin Receptor‐Neprilysin Inhibitors in Patients With Atrial Fibrillation and Heart Failure From 2021 to 2022: An Analysis of Real‐World Data
Key Points
Key points are not available for this paper at this time.
Abstract
Contemporary use of sodium-glucose cotransporter-2 inhibitors (SGLT2i) and angiotensin receptor-neprilysin inhibitors (ARNi) in patients with atrial fibrillation (AF) and heart failure (HF) has not been described.
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...
Authors
Álvaro Alonso
Broad Institute
A
Alanna A. Morris
Heart Failure & Transplant
A
Ashley I. Naimi
Emory University
Journals
Journal of the American Heart Association
Actions
Institutions
University of Minnesota
Emory University
References and Citations
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...